Biocon Ltd and Mylan NV on Friday announced that they have received approval from the United States Food and Drug Administration (FDA) for the launch of its insulin glargine injection Semglee which is meant to control high blood sugar in adults with diabetes
“The US FDA has approved the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and pre-filled pen presentations, to control high blood sugar in adults with Type-2 diabetes and adult and pediatric patients with Type-1 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications,” the companies said in a statement.
Semglee has been developed by the India-based Biocon Biologics in partnership with Mylan. It was approved by the USFDA as a drug product under the 505(b)(2) NDA pathway.
With the product being deemed as a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products, it becomes the third biologics launched by Biocon in the US.
The approval for the product was sought based on a “comprehensive analytical, preclinical and clinical programmeme (including the INSTRIDE studies).” This programme confirmed the PK/PD, efficacy, safety and immunogenicity of the injection in patients with Type-1 and Type-2 diabetes.
Kiran Mazumdar Shaw, Chairperson, Biocon, said: “The approval of our insulin glargine by the US FDA marks the culmination of a long journey. As an organisation committed to making insulin-based therapy increasingly accessible for people with diabetes globally, I am glad this approval will enable us to serve the needs of patients in the US The approval is also an endorsement of our science, scale and expertise to develop high quality, more affordable insulins and shift the access paradigm in favour of patients, taking us closer to realizing our aspiration of reaching ‘one in five’ insulin-dependent people with diabetes worldwide.”
The commercialisation of this insulin glargine injection in the US will further expand the affordability and accessibility of such products for diabetic patients as per the company.
“This approval is an important milestone, first and foremost for the millions of patients living with diabetes in the US as we seek to expand their access to insulin through more affordable treatment options,” said Mylan CEO Heather Bresch.
June 12, 2020
A letter from the Editor
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.
Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.
In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.
We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism